Is adjuvant ribociclib ready for prime time?

Sarah Sammons shared a post by Paolo Tarantino, on X:

“The number needed to treat (NNT) to prevent one distant recurrence is 37 (100/2.7) for ribociclib, and estimated cost of around $400,000, for 3 years of therapy for one individual patient, and the cost to prevent one distant disease-free recurrence is $14.8 million.”

Quoting Paolo Tarantino‘s post:

“Hot off the press in Annals of Oncology: Is adjuvant ribociclib ready for prime time?

Authors: A. Natarajan, S.M. Tolaney

Recommended read in preparation for the NATALEE 4y update at ESMO24.”

Source: Sarah Sammons/X and Paolo Tarantino/X

Sarah Sammons is a medical oncologist at Dana-Farber’s Breast Oncology Center specializing in treating patients with all stages of breast cancer. She is particularly focusing on improving outcomes for those with metastatic breast cancer. Through leading numerous clinical trials, she has developed new treatment options for breast cancer patients. Additionally, Dr. Sammons is skilled in treating brain metastases.

Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.